<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908904</url>
  </required_header>
  <id_info>
    <org_study_id>cafestol.acute.t2d</org_study_id>
    <nct_id>NCT04908904</nct_id>
  </id_info>
  <brief_title>Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.</brief_title>
  <official_title>Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute, double-blinded, randomized, cross-over cafestol intervention study with sixteen&#xD;
      participants with T2D participating in two OGTTs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an acute, double-blinded, randomized, cross-over intervention study with sixteen&#xD;
      participants with T2D. Initially, a blood sample is obtained (t=-15 min) and at time point 0,&#xD;
      the participants will ingest a tablet containing either 12 mg cafestol or placebo.&#xD;
      Immediately hereafter an OGTT commences with ingestion of a 75 g glucose solution. In the&#xD;
      following 3 hours blood samples are collected at time points 0, 15, 30, 60, 90, 120 and 180&#xD;
      min. The samples will be used for determination of plasma glucose, insulin and cafestol, as&#xD;
      well as GLP-1 and GIP. After a one-week washout period, the subject will undergo the same&#xD;
      set-up again, however now with the opposite intervention / placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve for glucose</measure>
    <time_frame>-15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution</time_frame>
    <description>Area under the curve for glucose during OGTT after ingestion of cafestol or placebo capsule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for insulin-response</measure>
    <time_frame>-15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution</time_frame>
    <description>Area under the curve for insulin response during OGTT after ingestion of cafestol or placebo capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for cafestol</measure>
    <time_frame>-15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution</time_frame>
    <description>Area under the curve for cafestol during OGTT after ingestion of cafestol or placebo capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for GLP-1</measure>
    <time_frame>-15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution</time_frame>
    <description>Area under the curve for GLP-1 (glucagon-like peptide-1) during OGTT after ingestion of cafestol or placebo capsule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for GIP</measure>
    <time_frame>-15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution</time_frame>
    <description>Area under the curve for GIP (Glucose-dependent insulinotropic polypeptide) during OGTT after ingestion of cafestol or placebo capsule</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Cafestol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 mg cafestol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cafestol</intervention_name>
    <description>Capsule with 12 mg cafestol</description>
    <arm_group_label>Cafestol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule without cafestol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes defined by standard Danish guidelines&#xD;
&#xD;
          -  HbA1c ≥48 mmol/mol unless successfully treated with antidiabetic drugs and/or&#xD;
             diet/exercise intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In treatment with insulin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Planned pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Significant comorbidity expected to unable the subject from completing visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fredrik B Mellbye, M.D.</last_name>
    <phone>+4526844425</phone>
    <email>fbmellbye@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren Gregersen, M.D. Ph.D</last_name>
    <phone>+4530134245</phone>
    <email>soeren.gregersen@aarhus.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Steno Diabetes Center Aarhus</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik B Mellbye, M.D.</last_name>
      <phone>+4526844425</phone>
      <email>fbmellbye@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

